Drug
Talabostat clinical trials
Also written BXCL701.
Includes 7 studies of Talabostat mesylate.
- studies test it
- 14
- open now
- 0
- in phase 3
- 2
- first study started
- 2005
How studies write it
Studies that test it under each name
Development codes
Combined with it in one product
Studies by the year they started
9 studies that test it; most in 2006 (3)
| Year | Studies |
|---|---|
| 2005 | 1 |
| 2006 | 3 |
| 2019 | 2 |
| 2020 | 1 |
| 2023 | 2 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 3
- Phase 2
- 9
- Phase 3
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 9 · Other 5
Point Therapeutics (7) · BioXcel Therapeutics Inc (2) · Eric Stephen Winer, MD (1) · Georgetown University (1) · National Institutes of Health Clinical Center (CC) (1) · M.D. Anderson Cancer Center (1) · University of Nebraska (1)
Often tested with
Tested in the same studies.
Pembrolizumab (3) · Docetaxel (2) · Rituximab (1) · Carboplatin (1) · Temozolomide (1) · Cisplatin (1) · Gemcitabine (1) · Pemetrexed (1)
Studies
Open first, then newest update. How each study uses talabostat is read from its arms, and is right about nine times in ten.
Testing it · 14
- BXCL701 Phase 1 R/R Acute Myeloid Leukemia or Myelodysplastic SyndromeActive, not recruitingPhase 1Eric Stephen Winer, MDNCT05703542Written as BXCL701
- BXCL701 and Pembrolizumab in Patients With Metastatic Pancreatic Ductal AdenocarcinomaActive, not recruitingPhase 2Georgetown UniversityNCT05558982Written as BXCL701
- A Pilot Study of BXCL701 in Patients With Pancreatic CancerWithdrawnEarly Phase 1BioXcel Therapeutics IncNCT04123574Written as Talabostat Mesylate
- A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype.CompletedPhase 1/2BioXcel Therapeutics IncNCT03910660Written as BXCL701 plus Pembrolizumab
- Talabostat and Pembrolizumab for the Treatment of Advanced Solid CancersTerminatedPhase 2M.D. Anderson Cancer CenterNCT04171219Written as Talabostat Mesylate
- Talabostat in Treating Patients With Metastatic Kidney CancerWithdrawnPhase 2University of NebraskaNCT00489710Written as talabostat mesylate
- Study of Talabostat and Rituximab in Advanced Chronic Lymphocytic Leukemia (CLL)CompletedPhase 2Point TherapeuticsNCT00086203Written as Talabostat mesylate (PT-100) tablets
- Talabostat Combined With Temozolomide or Carboplatin in Treating Young Patients With Relapsed or Refractory Brain Tumors or Other Solid TumorsCompletedPhase 1National Institutes of Health Clinical Center (CC)NCT00303940Written as talabostat mesylate
- Study of Talabostat and Docetaxel in Advanced Non-Small Cell Lung CancerCompletedPhase 2Point TherapeuticsNCT00080080Written as talabostat (PT-100) tablets
- Study of Talabostat in Advanced MelanomaCompletedPhase 2Point TherapeuticsNCT00083239Written as talabostat (PT-100) tablets
- Study of Talabostat and Cisplatin in Advanced MelanomaCompletedPhase 2Point TherapeuticsNCT00083252Written as talabostat (PT-100) tablets
- Study of Talabostat + Docetaxel Versus Docetaxel in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) After Failure of Platinum-Based ChemotherapyTerminatedPhase 3Point TherapeuticsNCT00243204Written as talabostat mesylate
- Trial of Talabostat and Gemcitabine in Patients With Stage IV Adenocarcinoma of the PancreasTerminatedPhase 2Point TherapeuticsNCT00116389Written as talabostat mesylate tablets
- Study of Talabostat and Pemetrexed vs. Pemetrexed in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) After Failure of Platinum-Based ChemotherapyTerminatedPhase 3Point TherapeuticsNCT00290017Written as talabostat
Codes
What other systems call talabostat · ClinicalTrials.gg INT004974
- MeSH (NLM) C514044talabostatOne source NLM
- UNII (FDA) KZ1O2SH88ZTALABOSTATConfirmed FDA, NLM, Wikidata
- Wikidata Q27282515talabostatConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C48264TalabostatOne source FDA
- DrugBank DB06182One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C514044 | talabostat | One source NLM |
| UNII (FDA) | KZ1O2SH88Z | TALABOSTAT | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27282515 | talabostat | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C48264 | Talabostat | One source FDA |
| DrugBank | DB06182 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.